Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.
FAIL · Does not pass the screen
36.62 USD
Price as of 5 Nov 2026Daily close, not a live quote
Screened 2026-11-05 · the tape above runs as of 20:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price36.62 USD at the 5 Nov 2026 close
Our value readUndervalued vs our fair value, as of 5 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.23, read 2026-11-02
Ethical does not pass the values gate
Price36.62 USD
Fair value47.00
Ethical score70.0/100
Value readUndervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-11-01Read Markup36.91-0.8% to today Distribution gives way to Markup after a 10% rise in 7 days
2026-10-25Read Distribution33.62+8.9% to today Markdown gives way to Distribution
2026-10-11Read Markdown34.21+7.0% to today Markup gives way to Markdown after a 14% rise in 14 weeks
2026-07-02Read Markup30.04+21.9% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Roivant Sciences Ltd holds its Markup at $36.62. Consolidating, no directional conviction, held for 18 days.
As held on the ledger · 2026-11-05
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 18 days
Price at the screen
$36.62
Valuation
N/A trailing · -20.99 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.10
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
1.88%
Below 33%
Interest-bearing debt is just 1.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
50.32%
Below 33%
Interest-bearing cash and securities are 50.3% of assets, above the one-third limit.
Fail
Receivables
38.35%
Below 49%
Money owed to the company is 38.4% of assets, under the 49% limit.
Pass
Revenue purity
100.00%
Below 5%
100.0% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Roivant Sciences's business is fine, but its cash and interest-bearing securities are about 50% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ROIV's ethical verdict changes
Today ROIV does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 5 Nov 2026: it trades at roughly a 19% discount to our $47.00 fair value, narrow competitive moat.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 22.1% discount to the base estimate.
Where our models see it going: fair-value estimate $47.00, with a range of $41.00 to $62.00, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Clinical bets rarely survive revenue cliffs
Picture a lab team watching a single antibody candidate move through trials while last year's sales evaporate. Roivant is exactly that story, a clinical stage biotech chasing IMVT-1402 and similar molecules with revenue already down 67 percent and margins stuck at zero.
We pass because the numbers refuse to support the analyst chorus. Forward earnings sit at a negative 22 times, return on equity is negative 8 percent, and the narrow moat offers little protection if the pipeline stumbles. A 16 percent gap to fair value looks tempting until you remember these are peak hopes priced in, not repeatable cash flow.
The real exposure sits in binary trial outcomes and repeated cash needs that can wipe out any margin of safety overnight. Ethical screen clears, yet the business remains a classic development gamble where low multiples signal distress more than value.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to United Kingdom and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ROIV trades on NASDAQ (the company is based in United Kingdom). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-01Markup · changed$36.91+9.8%Entry 10
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 9.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 150%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (12 analysts) rates it strong buy, with a mean price target of $39. Insiders have been net sellers over the past quarter.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 150%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (12 analysts) rates it strong buy, with a mean price target of $39. Insiders have been net sellers over the past quarter.
2026-10-18Markdown$33.62-1.7%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 30% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 150%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (12 analysts) rates it strong buy, with a mean price target of $39. Insiders have been net sellers over the past quarter.
2026-10-11Markdown · changed$34.21-14.0%Entry 7
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 14.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 30% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 150%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (12 analysts) rates it strong buy, with a mean price target of $39. Insiders have been net sellers over the past quarter. Since the last review it its composite score rose.
2026-10-02Markup$39.77+16.4%Entry 6
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 16.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 30% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 150%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (12 analysts) rates it strong buy, with a mean price target of $39. Insiders have been net sellers over the past quarter.
2026-09-11Markup$34.18+1.0%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 30% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 150%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (12 analysts) rates it strong buy, with a mean price target of $39.
2026-08-11Markup$33.84+12.6%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 30% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 150%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (12 analysts) rates it strong buy, with a mean price target of $39.
2026-07-18Markup$30.04+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 30% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 150%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (12 analysts) rates it strong buy, with a mean price target of $39.
2026-07-03Markup$30.04+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$30.04Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.